Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GPR4 | P46093 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240646 | 0.94 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2L3MBTL1GPR4ADORA1 | |
| SCHEMBL18497293 | 0.89 | KMT2A (0.39) | SMN1; SMN2USP2L3MBTL1GPR4ADORA1 | |
| SCHEMBL25169698 | 0.86 | USP2 (0.43) | SMN1; SMN2USP2HPGDEPHX2ALDH1A1 | |
| SCHEMBL28389225 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2USP2L3MBTL1GPR4ADORA1 | |
| SCHEMBL3494375 | 0.85 | SMN1; SMN2 (0.47) | SMN1; SMN2USP2L3MBTL1ADORA1KMT2A | |
| SCHEMBL22655647 | 0.84 | L3MBTL1 (0.39) | SMN1; SMN2USP2L3MBTL1ADORA1KMT2A | |
| SCHEMBL4689282 | 0.84 | USP2 (0.41) | SMN1; SMN2USP2L3MBTL1GPR4ADORA1 | |
| SCHEMBL21551293 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2L3MBTL1ADORA1KMT2A | |
| SCHEMBL18044513 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2L3MBTL1ADORA1KMT2A | |
| SCHEMBL24012274 | 0.83 | USP2 (0.44) | SMN1; SMN2USP2GPR4HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391687-B2 | Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| EP-3919490-B1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO LTD (CN) | 2025-04-02 | — | — | EP | disclosed |
| CN-113166142-B | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3919490-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-113242857-A | Preparation and application of imidazo aromatic ring compounds | 上海轶诺药业有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-113166142-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-111171019-A | Five-membered and six-membered heterocyclic compounds and application thereof as protein receptor kinase inhibitors | 上海轶诺药业有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111039946-A | Preparation and application of imidazo aromatic ring compounds | 上海轶诺药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008106058-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391687-B2 | Five-and-six-membered heterocyclic compound and use thereof as protein receptor kinase inhibitor | GRK6, GRK3, ERBB2 | SMN1; SMN2 3448/4885USP2 3279/4885L3MBTL1 3893/4885 |
| US-20220144827-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS PROTEIN RECEPTOR KINASE INHIBITOR | GRK6, GRK3, ERBB2 | SMN1; SMN2 3448/4885USP2 3279/4885L3MBTL1 3893/4885 |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | SMN1; SMN2 4664/4885USP2 3510/4885L3MBTL1 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.